Under the terms of the agreement for the study phase, ITM has partnered with Nordic Nanovector to support its clinical development.
At the same time, both parties signed a commercial agreement for the supply of EndolucinBeta post Marketing Approval of Betalutin.
Additional terms of the agreement are not disclosed.
EndolucinBeta, radiolabeled to anti-CD37 murine antibody lilotomab, is an active component of Betalutin, a next generation radioimmuno conjugate currently under clinical development in patients who suffer from Non-Hodgkin Lymphoma. Betalutin is a drug candidate with an excellent profile.
As well as leveraging an alternative therapeutic target (anti-CD37 antigen) in recurrent lymphoma patients who have relapsed following anti-CD20-based therapy, it has shown durable responses in heavily pre-treated NHL patients after a one-time administration, combined with a predictable and manageable toxicity, an important feature for elderly NHL patients who may not be suited to chemotherapy.
EndolucinBeta, a radiopharmaceutical precursor, is used in Targeted Radionuclide Therapy in the field of Precision Oncology and has marketing authorization in the EU.
Radiolabeled to disease-specific targeting molecules like antibodies or peptides, the tumor tissue is precisely destroyed by cytotoxic doses of ionizing radiation.
ITM has developed a unique methodology to produce a particularly highly pure form of Lutetium-177. No-carrier-added Lutetium-177 contains no metastable Lutetium-177m, therefore there is no need for cost intensive clinical waste management.
This is especially important in countries with a release limit of Lutetium-177m into public sewage systems.
Akeso presents positive results from registrational Phase III study of ivonescimab
FDA grants Priority Review to Genentech's Enspryng for MOGAD
Seismic Pharmaceuticals enrols first patient in istaroxime global Phase 3 trial in cardiogenic shock
BioEdge Research Labs advances transparency in research compound documentation
Insilico Medicine doses first patient in Phase III trial of rentosertib
BridgeBio reports exploratory PROPEL 3 data showing wider clinical trends for oral infigratinib
Tyra Biosciences declares positive Phase 2 results for oral dabogratinib in bladder cancer
Harbour BioMed partner raises USD225m to advance neoadjuvant immuno-oncology therapy porustobart
Kazia Therapeutics doses first patient in paediatric AT/RT study
Fusion Antibodies secures Canadian patent for OptiMAL
Revvity to acquire Human Cell Design to expand metabolic disease drug discovery capabilities
Biophytis expands BIO101 obesity study to assess weight regain
THX Pharma secures European patent for Batten-1 in juvenile Batten disease
Orphalan commences Phase 3 study of trientine therapy in Wilson disease